RxDoctor Payments Data

Jennifer Cothron

Nurse Practitioner · Birmingham, ALNPI 1083067037

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 628 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,947in general payments, 2019–2025

Across 628 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Grifols USA, LLC$863
  • Boehringer Ingelheim$726
  • Takeda Pharmaceuticals U.S.A., Inc.$690
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$12,72598%
  • Education$2222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,947 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$43,828
Medicare patients
376
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter199$174,085
Breo ElliptaFluticasone/Vilanterol122$64,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$22,653
Spiriva HandihalerTiotropium Bromide31$19,320
Spiriva RespimatTiotropium Bromide22$19,005
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,092
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,927
SymbicortBudesonide/Formoterol Fumarate36$8,460
Advair HfaFluticasone Propion/Salmeterol13$6,193
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,809
Wixela InhubFluticasone Propion/Salmeterol18$3,817
Albuterol Sulfate HfaAlbuterol Sulfate204$3,716
Arnuity ElliptaFluticasone Furoate14$3,249
Montelukast Sodium138$2,196
Ipratropium Bromide11$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,342$256,208355 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,564$31,11462 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$726$28,93241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →